Security
Eli Lilly (LLY) Research Hub
Eli Lilly (LLY) continues to capture significant institutional attention, highlighted by record-breaking clinical data for its weight loss candidate, retatrutide. The company remains a focal point in high-conviction investment strategies like the J.P. Morgan Analyst Focus List, which emphasizes top-tier growth and performance relative to the S&P 500. Beyond its metabolic portfolio, LLY is strategically positioned within the "Longevity" investment theme, as seniors emerge as a powerful economic force driving demand for vitality-focused healthcare and wellness. While the broader biopharma sector sees a shift toward the IL-23 class in immunology, analysts maintain a pro-risk stance on high-performing U.S. equities like LLY despite moderated global growth forecasts of 2.6%. This outlook is supported by robust 2026 growth expectations for technology and healthcare sectors that demonstrate strong innovation and successful trial outcomes. Ultimately, LLY’s trajectory is framed by its leadership in the obesity market and its alignment with long-term demographic shifts toward healthy aging.
52 reports available
Americas Morning Research Summary
This report provides a summary of Barclays Equity Research publications for June 10, 2026, covering various sectors including consumer goods, technology, healthcare, and financials.
Americas Morning Research Summary
A comprehensive daily summary of Barclays' equity research across the Americas, focusing on significant rating changes in tech and healthcare, and the accelerating impact of AI on market dynamics.
Americas Morning Research Summary
This report summarizes Barclays' equity research for May 26, 2026, featuring price target changes and sector updates across banking, retail, and healthcare.
Americas Morning Research Summary
This morning summary highlights Barclays' initiation of coverage on the Metals & Mining sector and significant model updates for major US corporations including Target, Deere, and FedEx. Key themes include accelerating AI infrastructure growth and strategic corporate portfolio simplifications.
Healthcare Conference Wrap-Up Key Themes And Takeaways
The report provides a comprehensive summary of the 47th Annual Global Healthcare Conference, highlighting key trends in M&A, AI integration, and obesity/cardiology therapeutics.
Global Healthcare: The Obesity Evolution
This report examines the global production capacity for Anti-Obesity Medication (AOM) peptides, specifically comparing Novo Nordisk's proprietary fermentation processes with synthetic (SPPS) manufacturing used by global CDMOs. It projects significant market growth for peptide API demand, largely driven by the adoption of oral GLP-1 therapies.
Longevity Weekly Pulse: The Next Phase of the Obesity Opportunity
European Morning Research Summary
Americas Morning Research Summary
All reports
Page 1 of 3
Americas Morning Research Summary
Barclays · Jun 10, 2026
Americas Morning Research Summary
Barclays · Jun 1, 2026
Americas Morning Research Summary
Barclays · May 26, 2026
Americas Morning Research Summary
Barclays · May 22, 2026
Healthcare Conference Wrap-Up Key Themes And Takeaways
Goldman Sachs · Jun 12, 2026
Global Healthcare: The Obesity Evolution
Goldman Sachs · Jun 5, 2026
Longevity Weekly Pulse: The Next Phase of the Obesity Opportunity
UBS · May 28, 2026
European Morning Research Summary
Barclays · May 11, 2026
Americas Morning Research Summary
Barclays · May 11, 2026
The Day Ahead North America
London Stock Exchange Group · Jun 8, 2026
Equity Compass
UBS · May 25, 2026
Annual Healthcare Conference Preview
Goldman Sachs · Jun 4, 2026
The Obesity Evolution: Global Anti-Obesity Medication Market Model Update
Goldman Sachs · Jun 3, 2026
The Point for North America
Citi · May 22, 2026
Reestablishing Momentum
Goldman Sachs · May 24, 2026
The Obesity Evolution: Pill Positioning Enhances Wegovy Competitiveness
Goldman Sachs · Jun 3, 2026
Ozempic Was the Warm Up: RETA Is the Killer
The Market Ear · May 25, 2026
Longevity Weekly Pulse: Robust 1Q26 for Consumer Companies
UBS · May 21, 2026
Longevity Weekly Pulse Key Pipeline Catalysts To Watch
UBS · May 14, 2026
Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals
William Blair · May 13, 2026
U.S. Analyst Focus List
J.P. Morgan · Jun 10, 2026
Recombinant DNA: 250 Years of US Innovation
UBS Financial Services Inc. · Jun 9, 2026
U.S. Analyst Focus List
J.P. Morgan · Jun 8, 2026
U.S. Analyst Focus List
J.P. Morgan · Jun 5, 2026